ECG changes during haloperidol and pimozide treatment of Tourette's disorder
Abstract
The ECG QTc interval was significantly prolonged by pimozide but not haloperidol or placebo in a randomized clinical trial with 40 patients with Tourette's disorder. However, no adverse cardiac effects or differences in rate, rhythm, or waveform were found.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).